不同ABCB1基因型乳腺癌患者应用紫杉醇的安全性研究

The study of safety in breast cancer patients with different ABCB1 geno type of Paclitaxel

目的研究不同ABCB1基因型乳腺癌患者在应用紫杉醇治疗时毒副作用的差异。方法根据是否进行紫杉醇药物基因检测,将我院2014年1月—2016年5月乳腺癌患者分成检测组、未检测组,每组各100例。患者中选择应用紫杉醇联合环磷酰胺化疗方案,且坚持完4周期化疗的患者入试验组。最终检测组中符合入组标准的53例患者编为试验一组,未检测组72例患者编为试验二组。统计并比较2组患者应用4周期后,出现Ⅲ度及其以上骨髓抑制的情况。结果试验一组出现严重骨髓抑制的仅为7.5%,试验二组出现严重骨髓抑制的多达43.1%。结论在乳腺癌患者中通过检测ABCB1基因型在一定程度上可以预测患者血液学毒性风险。

Objective To study different ABCB1 genotype patients with breast cancer incidence of side effects in the application of paclitaxel. The necessity of drug gene detection has been detected before the treatment of paclitaxel in the patients with breast cancer. Methods According to whether to detect paclitaxel drug gene, the patients with breast cancer from January 2014 to March 2016 in our hospital were divided into two groups：the detection group and the non detection group,each group of 100 cases. The patients in chemotherapy of paclitaxel combined with cyclophosphamide for four cycles in the two groups were selected to be the experimental groups. Finally,53 patients in the detection group were enrolled in the experimental group 1,and 72 patients in the non detection group were enrolled in the group 2. Statistics and comparison about the risk of Ⅲ degree and over bone marrow suppression in the patients of the two experimental groups after chemotherapy of 4 cycles was carried out. Results The percent of the patients appeared severe bone marrow suppression was only 11.3% in the experimental group 1,but 58.3% in the experimental group 2. Conclusion In patients with breast cancer by detecting ABCB1 genotype in a certain extent can predict a patient＇s risk of toxicity of hematology.